Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goalrttnews·Jul 2 at 09:15 AMNVS-1.00%VRTX-0.32%
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ CancerCoinLive·Jul 2 at 05:33 AM00013+1.81%HCM+2.59%
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification | HCM Stock NewsStockTitan·Jul 1 at 07:30 PMHCM+2.59%
HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock NewsStockTitan·Jun 29 at 07:30 PM00013+1.81%HCM+2.59%
REG - Hutchmed China Ltd - Announcement on blocklisting six monthly returnLondon Stock Exchange·Jun 29 at 03:30 AMHCM+2.59%00013+1.81%
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trialbenzinga_article·Jun 25 at 11:08 AM00013+1.81%HCM+2.59%
HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive CholangiocarcinomaTip Ranks·Jun 24 at 07:07 PMHCM+2.59%00013+1.81%
